ClinicalTrials.gg
CompletedNCT01215968Updated Oct 7, 2014Results posted

A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
44th of 54
38 · median 159
Started
2010
with 6 others
Phase 1
15 of 54
none open now
Registered
10th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 44th largest by enrollment, is one of 7 that started in 2010, is one of 15 in phase 1, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary purpose of this Study is to help answer the following research question(s).

  • How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes?
  • How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)?
  • Is LY2189265 safe and are any side effects associated with it?

The study will be participant-blind in Week 1, and participant- and investigator-blind from Week 2 through Week 5.

Each participant will receive placebo on Week 1 and once-weekly doses of LY2189265 or Placebo on Weeks 2 to 5. Participants taking metformin for the treatment of Type 2 Diabetes Mellitus (T2DM) will continue taking metformin as part of the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are males or females, diagnosed with Type 2 Diabetes Mellitus for greater than or equal to 3 months prior to screening.
  2. Male patients agree to use a reliable method of during the study and for 3 months following the last dose of study drug. Female patients must be of non- due to surgical sterilization or menopause.
  3. Have a (BMI) between 18.5 and 40.0 kilogram/square meter (kg/m²), inclusive.
  4. Have Type 2 Diabetes Mellitus controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (e.g. metformin) prior to screening, and have been taking a stable dose for >7 days prior to the first dosing occasion.
  5. Have a fasting blood glucose value at screening >126 milligram/deciliter (mg/dL) (7.0 [millimoles/liter] mmol/L) for patients on a controlled diet, and >108 mg/dL (6.0 mmol/L) for patients on oral antidiabetic medication, with an upper limit of 180 mg/dL (approximately 9.9 mmol/L) in each case.
  6. Have a (HbA1c) (indicates what your average blood glucose level has been in the past 3 months) value at screening (or within 4 weeks prior to screening) of 6.5% to 9.5%. If HbA1c is between 6.1% and 6.5%, patients may participate in the study providing they are receiving permissible oral antidiabetic medication.
  7. Have clinical laboratory test results within normal ranges as determined by the study doctor.
  8. Can provide enough blood in order to undergo the blood sampling required for the study.
  9. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.
  10. Have signed the consent form approved by Lilly and the Ethical Review Board (ERB) governing the site.

Exclusion criteria

Exclusion Criteria:

  1. Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  2. Have previously been exposed to, or have known allergies to glucagon-like-peptide-1 (GLP-1)-related compounds including LY2189265.
  3. Are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265 or have received glucagon-like peptides or incretin mimetics in the past 3 months.
  4. Have taken certain Type 2 Diabetes medications within 30 days prior to screening.
  5. Have an abnormality in the (ECG) performed at screening.
  6. Have poorly controlled high blood pressure (systolic blood pressure >160 millimeters of mercury [mmHg] and/or diastolic blood pressure >100 mmHg).
  7. Have a history or presence of respiratory, liver, kidney, hormonal, blood, or neurological disorders which may put the patient at risk when taking the study medication; or may interfere with the interpretation of data.
  8. Have a history or presence of cardiovascular disorder within the last year, or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty.
  9. Have a history or presence of pancreatitis or certain gastrointestinal disorders.
  10. Have been exposed to radiation from clinical trials and from diagnostic X-ray or are exposed routinely via your job worker.
  11. Have any non-removable metal objects such as metal plates, screws etc. in their chest or abdominal area.
  12. Have had acute diarrhea or constipation within 14 days of study screening.
  13. Show evidence of significant active neuropsychiatric disease.
  14. Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.
  15. Intend to start new medication during the study, including over-the-counter and herbal medication.
  16. Have donated blood of more than 500 milliliter (mL) within the last month prior to screening.
  17. Have an average weekly alcohol intake that exceeds the study centre's guidelines and are unwilling to adhere to the alcohol restrictions in place throughout the study.
  18. Smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to stop smoking on the day of medication administration or are unable to abide by clinical research unit (CRU) restrictions on other inpatient days.
  19. Are allergic to eggs or other components of the meals to be served.
  20. Are patients who, in the opinion of the investigator, are in any way unsuitable to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5. Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall. Participants regularly taking metformin will continue their normal dosing regimen throughout the study.

    Drug: Placebo

  • Experimental
    LY2189265

    Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5. 1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall. Participants regularly taking metformin will continue their normal dosing regimen throughout the study.

    Biological: LY2189265 · Drug: Placebo

Interventions

  • BiologicalLY2189265

    1.5 mg administered subcutaneously

  • DrugPlacebo

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy

    After at least 8 hours fasting, participants received a radiolabeled breakfast containing technetium-99m-tin colloid (99mTc-tin colloid). After which serial anterior and posterior scintigraphy images were taken. Data presented are the time required for 50% of radioactivity to be emptied from stomach. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for weeks.

    Time frame: Days 3, 10,17, 24 and 31

Secondary outcomes

  1. Area Under the Curve (AUC) of Metformin

    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as AUC) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying. AUC of metformin was calculated during one dosing interval.

    Time frame: Days 3, 17 and 31

  2. Maximum Concentration (Cmax) of Metformin

    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Cmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

    Time frame: Days 3, 17 and 31

  3. Time to Maximum Concentration (Tmax) of Metformin

    Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Tmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

    Time frame: Days 3, 17 and 31

  4. Number of Participants With Clinically Significant Effects

    Adverse events (AEs) were considered clinically significant effects. A summary of serious adverse events (SAEs) and other nonserious AEs are located in the Reported Adverse Event section.

    Time frame: Baseline through 5 weeks

07

Results

Posted Oct 7, 2014

Participant flow

Participant flow — Overall Study
MilestonePlaceboLY2189265
Started1325
Received at least 1 dose of study drug1324
Completed1118
Not completed27
Withdrew: Adverse event02
Withdrew: Protocol violation24
Withdrew: Not received study drug01

Outcome measures

PrimaryTime Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy

After at least 8 hours fasting, participants received a radiolabeled breakfast containing technetium-99m-tin colloid (99mTc-tin colloid). After which serial anterior and posterior scintigraphy images were taken. Data presented are the time required for 50% of radioactivity to be emptied from stomach. The results presented are Geometric Least Squares (LS) Mean. LS Mean values were controlled for weeks.

Time frame:
Days 3, 10,17, 24 and 31
Reported as:
Geometric mean · hours
Time Required for 50% of Radioactivity To Be Emptied From the Stomach by Scintigraphy
hoursPlaceboLY2189265
Day 31.44 (1.22 to 1.69)1.72 (1.43 to 2.06)
Day 101.41 (1.20 to 1.66)3.77 (3.15 to 4.51)
Day 17 (n=9, 14)1.60 (1.36 to 1.89)3.32 (2.76 to 4.00)
Day 24 (n=9, 14)1.47 (1.25 to 1.73)3.28 (2.72 to 3.94)
Day 31 (n=10, 13)1.46 (1.24 to 1.71)3.15 (2.61 to 3.81)
Statistical analysis
  • LY2189265 · Mixed Linear effects model analyses · Ratio of geometric ls mean: 2.19 · 90% CI 1.83 to 2.62Ratio is the Geometric LS Means of Day 10 over Day 3.
  • LY2189265 · Mixed Linear effects model analyses · Ratio of geometric ls mean: 1.94 · 90% CI 1.61 to 2.33Ratio is the Geometric LS Means of Day 17 over Day 3.
  • LY2189265 · Mixed Linear effects model analyses · Ratio of geometric ls mean: 1.91 · 90% CI 1.59 to 2.29Ratio is the Geometric LS Means of Day 24 over Day 3.
  • LY2189265 · Mixed Linear effects model analyses · Ratio of geometric ls mean: 1.84 · 90% CI 1.52 to 2.22Ratio is the Geometric LS Means of Day 31 over Day 3.
SecondaryArea Under the Curve (AUC) of Metformin

Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as AUC) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying. AUC of metformin was calculated during one dosing interval.

Time frame:
Days 3, 17 and 31
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
Area Under the Curve (AUC) of Metformin
nanograms*hour/milliliter (ng*h/mL)PlaceboLY2189265
Day 313600 ± 4913700 ± 40
Day 1714600 ± 4715300 ± 43
Day 31 (n=6, 11)14600 ± 4715800 ± 43
SecondaryMaximum Concentration (Cmax) of Metformin

Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Cmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

Time frame:
Days 3, 17 and 31
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Maximum Concentration (Cmax) of Metformin
nanograms/milliliter (ng/mL)PlaceboLY2189265
Day 31610 ± 481690 ± 47
Day 171690 ± 481500 ± 53
Day 31 (n=6, 11)1770 ± 461680 ± 44
SecondaryTime to Maximum Concentration (Tmax) of Metformin

Metformin was used as a secondary marker in the study to correlate the effect of LY2189265 on gastric emptying to the pharmacokinetics (PK) (measured as Tmax) of concomitant medications. Participants taking metformin for treatment of Type 2 Diabetes Mellitus (T2DM) underwent PK assessments for metformin in parallel to their scintigraphy assessments for gastric emptying.

Time frame:
Days 3, 17 and 31
Reported as:
Median · hour
Time to Maximum Concentration (Tmax) of Metformin
hourPlaceboLY2189265
Day 31.00 (1.00 to 2.03)2.02 (1.00 to 4.10)
Day 172.02 (1.02 to 8.00)2.05 (0.96 to 4.02)
Day 31 (n=6, 11)1.53 (0.98 to 4.00)2.02 (1.00 to 4.03)
SecondaryNumber of Participants With Clinically Significant Effects

Adverse events (AEs) were considered clinically significant effects. A summary of serious adverse events (SAEs) and other nonserious AEs are located in the Reported Adverse Event section.

Time frame:
Baseline through 5 weeks
Reported as:
Number · participants
Number of Participants With Clinically Significant Effects
participantsPlaceboPlacebo (Week 1)LY2189265
SAEs000
Other nonserious AEs71120

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/13 (0%)7/13 (53.8%)
Placebo (Week 1)—0/25 (0%)11/25 (44%)
LY2189265—0/24 (0%)20/24 (83.3%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboPlacebo (Week 1)LY2189265
NauseaGastrointestinal disorders3/131/2512/24
Decreased appetiteMetabolism and nutrition disorders1/130/258/24
DiarrhoeaGastrointestinal disorders1/132/257/24
DyspepsiaGastrointestinal disorders0/131/257/24
VomitingGastrointestinal disorders1/130/256/24
EructationGastrointestinal disorders1/130/255/24
HeadacheNervous system disorders2/134/255/24
Abdominal distensionGastrointestinal disorders1/130/254/24
NasopharyngitisInfections and infestations0/131/254/24
DizzinessNervous system disorders1/132/254/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLY2189265Total
Mean52.0 ± 14.058.9 ± 9.856.5 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLY2189265Total
Female257
Male112031
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLY2189265Total
Hispanic or Latino000
Not Hispanic or Latino132538
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLY2189265Total
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander000
Black or African American000
White102434
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboLY2189265Total
United Kingdom132538
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Glasgow, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2010
First posted
Oct 7, 2010
Start
Sep 2010
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01215968
Responsible party
Sponsor
First posted
Oct 7, 2010
Start date
Sep 2010
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion